ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies

Sandrine Lecour, Hans E. Bøtker, Gianluigi Condorelli, Sean M. Davidson, David Garcia-Dorado, Felix B. Engel, P. Ferdinándy, Gerd Heusch, Rosalinda Madonna, Michel Ovize, Marisol Ruiz-Meana, Rainer Schulz, Joost P G Sluijter, Linda W. Van Laake, Derek M. Yellon, Derek J. Hausenloy

Research output: Article

78 Citations (Scopus)

Abstract

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart fromthe detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

Original languageEnglish
Pages (from-to)399-411
Number of pages13
JournalCardiovascular Research
Volume104
Issue number3
DOIs
Publication statusPublished - dec. 1 2014

Fingerprint

Cell Biology
Myocardial Ischemia
Therapeutics
Reperfusion Injury
Research
Cause of Death
Animal Models

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Lecour, S., Bøtker, H. E., Condorelli, G., Davidson, S. M., Garcia-Dorado, D., Engel, F. B., ... Hausenloy, D. J. (2014). ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies. Cardiovascular Research, 104(3), 399-411. https://doi.org/10.1093/cvr/cvu225

ESC working group cellular biology of the heart : Position paper: Improving the preclinical assessment of novel cardioprotective therapies. / Lecour, Sandrine; Bøtker, Hans E.; Condorelli, Gianluigi; Davidson, Sean M.; Garcia-Dorado, David; Engel, Felix B.; Ferdinándy, P.; Heusch, Gerd; Madonna, Rosalinda; Ovize, Michel; Ruiz-Meana, Marisol; Schulz, Rainer; Sluijter, Joost P G; Van Laake, Linda W.; Yellon, Derek M.; Hausenloy, Derek J.

In: Cardiovascular Research, Vol. 104, No. 3, 01.12.2014, p. 399-411.

Research output: Article

Lecour, S, Bøtker, HE, Condorelli, G, Davidson, SM, Garcia-Dorado, D, Engel, FB, Ferdinándy, P, Heusch, G, Madonna, R, Ovize, M, Ruiz-Meana, M, Schulz, R, Sluijter, JPG, Van Laake, LW, Yellon, DM & Hausenloy, DJ 2014, 'ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies', Cardiovascular Research, vol. 104, no. 3, pp. 399-411. https://doi.org/10.1093/cvr/cvu225
Lecour, Sandrine ; Bøtker, Hans E. ; Condorelli, Gianluigi ; Davidson, Sean M. ; Garcia-Dorado, David ; Engel, Felix B. ; Ferdinándy, P. ; Heusch, Gerd ; Madonna, Rosalinda ; Ovize, Michel ; Ruiz-Meana, Marisol ; Schulz, Rainer ; Sluijter, Joost P G ; Van Laake, Linda W. ; Yellon, Derek M. ; Hausenloy, Derek J. / ESC working group cellular biology of the heart : Position paper: Improving the preclinical assessment of novel cardioprotective therapies. In: Cardiovascular Research. 2014 ; Vol. 104, No. 3. pp. 399-411.
@article{25ffedbe7f0747fba1db058f85961eeb,
title = "ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies",
abstract = "Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart fromthe detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.",
keywords = "Animal models, Cardioprotection, Ischaemia, Myocardial infarction, Reperfusion",
author = "Sandrine Lecour and B{\o}tker, {Hans E.} and Gianluigi Condorelli and Davidson, {Sean M.} and David Garcia-Dorado and Engel, {Felix B.} and P. Ferdin{\'a}ndy and Gerd Heusch and Rosalinda Madonna and Michel Ovize and Marisol Ruiz-Meana and Rainer Schulz and Sluijter, {Joost P G} and {Van Laake}, {Linda W.} and Yellon, {Derek M.} and Hausenloy, {Derek J.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1093/cvr/cvu225",
language = "English",
volume = "104",
pages = "399--411",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - ESC working group cellular biology of the heart

T2 - Position paper: Improving the preclinical assessment of novel cardioprotective therapies

AU - Lecour, Sandrine

AU - Bøtker, Hans E.

AU - Condorelli, Gianluigi

AU - Davidson, Sean M.

AU - Garcia-Dorado, David

AU - Engel, Felix B.

AU - Ferdinándy, P.

AU - Heusch, Gerd

AU - Madonna, Rosalinda

AU - Ovize, Michel

AU - Ruiz-Meana, Marisol

AU - Schulz, Rainer

AU - Sluijter, Joost P G

AU - Van Laake, Linda W.

AU - Yellon, Derek M.

AU - Hausenloy, Derek J.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart fromthe detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

AB - Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart fromthe detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of CardiologyWorkingGroup Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

KW - Animal models

KW - Cardioprotection

KW - Ischaemia

KW - Myocardial infarction

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84924175586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924175586&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvu225

DO - 10.1093/cvr/cvu225

M3 - Article

C2 - 25344369

AN - SCOPUS:84924175586

VL - 104

SP - 399

EP - 411

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -